China grants EUA to Covid-19 vaccineCovid-19 vaccine against XBB descendent lineages
2023-06-09
疫苗紧急使用授权上市批准临床研究信使RNA
Preview
来源: Pharmaceutical Technology
The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy 14 days after injection. Credit: WestVac BioPharma Co., Ltd./ CNW.
WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta) protein vaccine (Sf9 cell).
This marks the world’s first Covid-19 vaccineCovid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - influenza [strains A/H1N1 + A/H3N2 + B/Hong Kong] vaccine GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vacci... GlobalData
View all
The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.
WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform.
The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 subvariants.
It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.
Trials demonstrated that the vaccine induced a high titer of neutralising antibodies against several subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.2.75, BQ.1, BA.5 and BF.7.
The vaccine demonstrated an excellent safety profile and 93.28% protective efficacy against XBB.1, XBB.1.5, and XBB1.9, 14 days after injection.
The results indicated that coviccine trivalent XBB.1.5 is a Covid-19 vaccineCovid-19 vaccine with a broad spectrum to tackle several prevalent subvariants in China and globally.
China’s authorities granted an EUA for WestVac Biopharma’s coviccine-recombinant Covid-19 vaccineCovid-19 vaccine (Sf9 cell) in December 2022.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。